About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tcrdtm1.1(cre/ERT2)Zhu
targeted mutation 1.1, Yuan Zhuang
MGI:6117766
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Rorctm3Litt/Rorctm3Litt
Tcrdtm1.1(cre/ERT2)Zhu/Tcrd+ 		B6.Cg-Rorctm3Litt Tcrdtm1.1(cre/ERT2)Zhu MGI:8449416
cn2
 		Slc2a1tm1.1Stma/Slc2a1tm1.1Stma
Tcrdtm1.1(cre/ERT2)Zhu/Tcrd+ 		involves: 129S1/Sv * C57BL/6J MGI:8449411
cn3
 		Slc2a1tm1.1Stma/Slc2a1+
Tcrdtm1.1(cre/ERT2)Zhu/Tcrd+ 		involves: 129S1/Sv * C57BL/6J MGI:8449412


Genotype
MGI:8449416
cn1
Allelic
Composition		 Rorctm3Litt/Rorctm3Litt
Tcrdtm1.1(cre/ERT2)Zhu/Tcrd+
Genetic
Background		 B6.Cg-Rorctm3Litt Tcrdtm1.1(cre/ERT2)Zhu
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rorctm3Litt mutation (1 available); any Rorc mutation (43 available)
Tcrdtm1.1(cre/ERT2)Zhu mutation (1 available); any Tcrd mutation (15 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
decreased tumor growth/size ( J:327132 )
• tamoxifen-treated mice subjected to azoxymethane-dextran sodium sulfate (AOM-DSS) show no differences in colon tumor numbers or burden but show smaller tumors after the second DSS cycle

hematopoietic system
abnormal gamma-delta intraepithelial T cell morphology ( J:327132 )
• tamoxifen-treated mice show decreased Vgamma6+ and Vgamma4+ gamma-delta T cell populations
• however, tamoxifen-treated mice do not show changes in CD8alpha-alpha-expressing gamma-delta T cells
• mice treated with tamoxifen at late stages show reduced frequency of PD-1+ and IL-17-producing tumor-infiltrating gamma-delta T cells
• tamoxifen-treated and AOM-DSS subjected mice show a 55% reduction in tumor-infiltrating Rorgammat+ gamma-delta T cells
• however, no difference in Rorgammat expression or IL-17 production among CD4+ T cells
abnormal monocyte morphology ( J:327132 )
• tamoxifen-treated and AOM-DSS subjected mice show a decrease in tumor-infiltrating CD11b+Gr-1int cells (inflammatory monocytes)
abnormal T cell physiology ( J:327132 )
• tumor-infiltrating CD8alpha-beta+ T cells from tamoxifen-treated and AOM-DSS subjected mice show increased IFN-gamma production

immune system
abnormal gamma-delta intraepithelial T cell morphology ( J:327132 )
• tamoxifen-treated mice show decreased Vgamma6+ and Vgamma4+ gamma-delta T cell populations
• however, tamoxifen-treated mice do not show changes in CD8alpha-alpha-expressing gamma-delta T cells
• mice treated with tamoxifen at late stages show reduced frequency of PD-1+ and IL-17-producing tumor-infiltrating gamma-delta T cells
• tamoxifen-treated and AOM-DSS subjected mice show a 55% reduction in tumor-infiltrating Rorgammat+ gamma-delta T cells
• however, no difference in Rorgammat expression or IL-17 production among CD4+ T cells
abnormal monocyte morphology ( J:327132 )
• tamoxifen-treated and AOM-DSS subjected mice show a decrease in tumor-infiltrating CD11b+Gr-1int cells (inflammatory monocytes)
abnormal T cell physiology ( J:327132 )
• tumor-infiltrating CD8alpha-beta+ T cells from tamoxifen-treated and AOM-DSS subjected mice show increased IFN-gamma production
increased interferon-gamma secretion ( J:327132 )
• tumor-infiltrating CD8alpha-beta+ T cells from tamoxifen-treated and azoxymethane-dextran sodium sulfate (AOM-DSS) subjected mice show increased IFN-gamma production




Genotype
MGI:8449411
cn2
Allelic
Composition		 Slc2a1tm1.1Stma/Slc2a1tm1.1Stma
Tcrdtm1.1(cre/ERT2)Zhu/Tcrd+
Genetic
Background		 involves: 129S1/Sv * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc2a1tm1.1Stma mutation (2 available); any Slc2a1 mutation (63 available)
Tcrdtm1.1(cre/ERT2)Zhu mutation (1 available); any Tcrd mutation (15 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal T cell physiology ( J:327132 )
• tamoxifen-treated mice subjected to AOM-DSS show a reduction in IFN-gamma production by tumor-infiltrating gamma-delta T cells

homeostasis/metabolism
increased incidence of tumors by chemical induction ( J:327132 )
• tamoxifen-treated mice subjected to azoxymethane-dextran sodium sulfate (AOM-DSS) show a higher colon tumor number and load compared to wild-type mice, without affecting tumor size
• however, late tamoxifen-treatment (after the second DSS cycle) has no effect on tumor load or tumor-infiltrating gamma-delta T cells

immune system
abnormal T cell physiology ( J:327132 )
• tamoxifen-treated mice subjected to AOM-DSS show a reduction in IFN-gamma production by tumor-infiltrating gamma-delta T cells
decreased interferon-gamma secretion ( J:327132 )
• tamoxifen-treated mice subjected to AOM-DSS show a reduction in IFN-gamma production by tumor-infiltrating gamma-delta T cells
• however, the frequency of IFN-gamma production by TCRalpabeta+CD8alphabeta+ cells is unaffected

neoplasm
increased incidence of tumors by chemical induction ( J:327132 )
• tamoxifen-treated mice subjected to azoxymethane-dextran sodium sulfate (AOM-DSS) show a higher colon tumor number and load compared to wild-type mice, without affecting tumor size
• however, late tamoxifen-treatment (after the second DSS cycle) has no effect on tumor load or tumor-infiltrating gamma-delta T cells




Genotype
MGI:8449412
cn3
Allelic
Composition		 Slc2a1tm1.1Stma/Slc2a1+
Tcrdtm1.1(cre/ERT2)Zhu/Tcrd+
Genetic
Background		 involves: 129S1/Sv * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc2a1tm1.1Stma mutation (2 available); any Slc2a1 mutation (63 available)
Tcrdtm1.1(cre/ERT2)Zhu mutation (1 available); any Tcrd mutation (15 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased incidence of tumors by chemical induction ( J:327132 )
• tamoxifen-treated mice subjected to azoxymethane-dextran sodium sulfate (AOM-DSS) show a higher colon tumor number and load compared to wild-type mice, without affecting tumor size
• however, no reduction in tumor-infiltrating gamma-delta/alpha-beta cell ratio or in the frequency of Vgamma7+ cells is seen in tamoxifen-treated mice

hematopoietic system
abnormal T cell physiology ( J:327132 )
• tamoxifen-treated mice subjected to AOM-DSS show a reduction in IFN-gamma production by tumor-infiltrating gamma-delta T cells

homeostasis/metabolism
increased incidence of tumors by chemical induction ( J:327132 )
• tamoxifen-treated mice subjected to azoxymethane-dextran sodium sulfate (AOM-DSS) show a higher colon tumor number and load compared to wild-type mice, without affecting tumor size
• however, no reduction in tumor-infiltrating gamma-delta/alpha-beta cell ratio or in the frequency of Vgamma7+ cells is seen in tamoxifen-treated mice

immune system
abnormal T cell physiology ( J:327132 )
• tamoxifen-treated mice subjected to AOM-DSS show a reduction in IFN-gamma production by tumor-infiltrating gamma-delta T cells
decreased interferon-gamma secretion ( J:327132 )
• tamoxifen-treated mice subjected to AOM-DSS show a reduction in IFN-gamma production by tumor-infiltrating gamma-delta T cells
• however, the frequency of IFN-gamma production by TCRalpabeta+CD8alphabeta+ cells is unaffected




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
09/15/2026
MGI 6.29 		The Jackson Laboratory